Medpace Holdings Inc (NASDAQ:MEDP) has been assigned an average rating of “Hold” from the ten research firms that are covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $37.25.
A number of research analysts have recently issued reports on the company. BidaskClub raised Medpace from a “hold” rating to a “buy” rating in a research note on Thursday, December 14th. Zacks Investment Research downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. William Blair downgraded Medpace from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 1st. They noted that the move was a valuation call. Robert W. Baird boosted their price objective on Medpace from $32.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, October 31st. Finally, Jefferies Group boosted their price objective on Medpace from $34.00 to $38.00 and gave the company a “hold” rating in a research note on Wednesday, November 1st.
Shares of Medpace (MEDP) traded up $0.33 during trading hours on Wednesday, hitting $38.03. The stock had a trading volume of 151,665 shares, compared to its average volume of 158,577. The firm has a market cap of $1,416.80, a P/E ratio of 55.93, a price-to-earnings-growth ratio of 1.60 and a beta of -0.76. The company has a debt-to-equity ratio of 0.36, a current ratio of 0.68 and a quick ratio of 0.68. Medpace has a 12 month low of $21.76 and a 12 month high of $39.64.
Hedge funds have recently bought and sold shares of the stock. First Quadrant L P CA acquired a new position in Medpace during the 3rd quarter worth approximately $119,000. MetLife Investment Advisors LLC acquired a new position in Medpace during the 4th quarter worth approximately $137,000. SG Americas Securities LLC acquired a new position in Medpace during the 4th quarter worth approximately $151,000. We Are One Seven LLC bought a new stake in Medpace during the 4th quarter worth approximately $211,000. Finally, Atria Investments LLC bought a new stake in Medpace during the 4th quarter worth approximately $211,000. 17.15% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2018/02/17/brokerages-set-medpace-holdings-inc-medp-price-target-at-37-25.html.
Medpace Company Profile
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.